Middle East respiratory syndrome - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Middle East respiratory syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Middle East respiratory syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Middle East respiratory syndrome: Overview
The Middle East respiratory syndrome (MERS) is a lethal zoonotic severe lung infection caused by a legal pathogen Middle East Respiratory Syndrome Coronavirus (MERS-CoV). It was first identified in humans in Saudi Arabia and Jordan in 2012. Coronaviruses are large (28–32 kb) single-stranded positive-sense RNA viruses. To enter host cells, MERS-CoV attaches to its receptor, dipeptidyl peptidase 4. Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Protease cleavage of the S protein is then required for virus–cell fusion and release of genomic RNA into the cytoplasm. Viral RNA transcription and replication occurs on double membrane vesicles and other membranous structures, which are derived from the endoplasmic reticulum. MERS can be confirmed by detection of viral nucleic acid or by serology. The presence of viral nucleic acid can be confirmed either by positive real-time reverse transcription PCR on at least two specific genomic targets or by a single positive target with sequencing of a second positive PCR product. No specific drug treatment exists for MERS and supportive treatment is the mainstay of management.
'Middle East respiratory syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Middle East respiratory syndrome pipeline landscape is provided which includes the disease overview and Middle East respiratory syndrome treatment guidelines. The assessment part of the report embraces, in depth Middle East respiratory syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Middle East respiratory syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Middle East respiratory syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Middle East respiratory syndrome Emerging Drugs
Further product details are provided in the report
Middle East respiratory syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Middle East respiratory syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Middle East respiratory syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Middle East respiratory syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Middle East respiratory syndrome drugs.
Middle East respiratory syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Middle East respiratory syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Middle East respiratory syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Middle East respiratory syndrome: Overview
The Middle East respiratory syndrome (MERS) is a lethal zoonotic severe lung infection caused by a legal pathogen Middle East Respiratory Syndrome Coronavirus (MERS-CoV). It was first identified in humans in Saudi Arabia and Jordan in 2012. Coronaviruses are large (28–32 kb) single-stranded positive-sense RNA viruses. To enter host cells, MERS-CoV attaches to its receptor, dipeptidyl peptidase 4. Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Protease cleavage of the S protein is then required for virus–cell fusion and release of genomic RNA into the cytoplasm. Viral RNA transcription and replication occurs on double membrane vesicles and other membranous structures, which are derived from the endoplasmic reticulum. MERS can be confirmed by detection of viral nucleic acid or by serology. The presence of viral nucleic acid can be confirmed either by positive real-time reverse transcription PCR on at least two specific genomic targets or by a single positive target with sequencing of a second positive PCR product. No specific drug treatment exists for MERS and supportive treatment is the mainstay of management.
'Middle East respiratory syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Middle East respiratory syndrome pipeline landscape is provided which includes the disease overview and Middle East respiratory syndrome treatment guidelines. The assessment part of the report embraces, in depth Middle East respiratory syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Middle East respiratory syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Middle East respiratory syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Middle East respiratory syndrome.
This segment of the Middle East respiratory syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Middle East respiratory syndrome Emerging Drugs
- INO-4700: Inovio Pharmaceuticals
- VTP-500: Vaccitech
Further product details are provided in the report
Middle East respiratory syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Middle East respiratory syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Middle East respiratory syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Middle East respiratory syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Middle East respiratory syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Middle East respiratory syndrome drugs.
Middle East respiratory syndrome Report Insights
- Middle East respiratory syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Middle East respiratory syndrome drugs?
- How many Middle East respiratory syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Middle East respiratory syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Middle East respiratory syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Middle East respiratory syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Middle East respiratory syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Middle East respiratory syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Middle East respiratory syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Middle East respiratory syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
INO-4700: Inovio Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
VTP-500: Vaccitech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Middle East respiratory syndrome coronavirus vaccine: Novavax
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Middle East respiratory syndrome Key Companies
Middle East respiratory syndrome Key Products
Middle East respiratory syndrome- Unmet Needs
Middle East respiratory syndrome- Market Drivers and Barriers
Middle East respiratory syndrome- Future Perspectives and Conclusion
Middle East respiratory syndrome Analyst Views
Middle East respiratory syndrome Key Companies
Appendix
Executive Summary
Middle East respiratory syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Middle East respiratory syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Middle East respiratory syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Middle East respiratory syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
INO-4700: Inovio Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
VTP-500: Vaccitech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Middle East respiratory syndrome coronavirus vaccine: Novavax
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Middle East respiratory syndrome Key Companies
Middle East respiratory syndrome Key Products
Middle East respiratory syndrome- Unmet Needs
Middle East respiratory syndrome- Market Drivers and Barriers
Middle East respiratory syndrome- Future Perspectives and Conclusion
Middle East respiratory syndrome Analyst Views
Middle East respiratory syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Middle East respiratory syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Middle East respiratory syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Middle East respiratory syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Middle East respiratory syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
